<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To compare detection of Barrett's <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> by systematic versus nonsystematic surveillance biopsy protocols </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Upper GI consultation and open-access endoscopy are provided jointly at Glasgow Royal Infirmary by medical and surgical teams </plain></SENT>
<SENT sid="2" pm="."><plain>The surgical team adopted annual systematic four-quadrant biopsy Barrett's surveillance in 1995 </plain></SENT>
<SENT sid="3" pm="."><plain>The medical team continued annual Barrett's surveillance with nonsystematic biopsy until 2004 </plain></SENT>
<SENT sid="4" pm="."><plain>We compare detection of Barrett's <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in unselected patients by these two biopsy strategies over 10 yr </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had &gt; or = 3 cm <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and histological proof of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients referred for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> management or with prevalent <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were excluded </plain></SENT>
<SENT sid="7" pm="."><plain>Cohort A (N = 180) had four-quadrant biopsy every 2 cm while cohort B (N = 182) had nonsystematic biopsies </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Cohort A versus cohort B: Median number of biopsies per endoscopy: 16 versus 4 </plain></SENT>
<SENT sid="9" pm="."><plain>Prevalence of low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (per patient): 18.9% versus 1.6% (P &lt;&lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Prevalence of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>: 2.8% versus 0% (P = 0.03) </plain></SENT>
<SENT sid="11" pm="."><plain>Incidence of low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>: 2.2% versus 6.6% (NS) </plain></SENT>
<SENT sid="12" pm="."><plain>Incidence of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>: 2.8% versus 0% (P = 0.03) </plain></SENT>
<SENT sid="13" pm="."><plain>Nine cohort A patients (total 5%, 1.4% per patient-year) were treated for HGD (eight endoscopically, one by esophagectomy) </plain></SENT>
<SENT sid="14" pm="."><plain>Two had intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="15" pm="."><plain>No cohort A patient developed <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancer</z:e> but three cohort B patients developed and died of invasive Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (0.6% per patient-year) </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: Patient age, gender, Barrett's segment length, and follow-up were similar (though not identical) in both cohorts, but confounding seems unlikely to account for a 13-fold difference in detection of prevalent <z:mpath ids='MPATH_589'>dysplasia</z:mpath> between the two groups </plain></SENT>
<SENT sid="17" pm="."><plain>Our data support the hypothesis that systematic four-quadrant biopsy is considerably more effective than nonsystematic biopsy sampling in detecting Barrett's <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and early <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="18" pm="."><plain>Greater biopsy numbers and the systematic pattern of biopsy taking may both contribute to this greater effectiveness </plain></SENT>
</text></document>